Artificial intelligence (AI) is rapidly transforming the field of oncology, enhancing the precision of cancer diagnostics and accelerating drug development processes. AI and machine learning technologies are improving the detection of early-stage cancers, pinpointing specific variants and recommending optimal therapeutic strategies.
Targeting Cancer Treatment
Lantern Pharma and Massive Bio are two examples of companies leveraging AI to refine patient treatment plans. Lantern Pharma uses a machine-learning platform to analyze patient’s genetic and health data to personalize cancer treatments, while Massive Bio’s AI platform helps oncologists uncover a broader range of treatment options for their patients, including the latest drugs and clinical trials.
Speeding Up Oncology Drug Development
AI’s ability to rapidly process extensive troves of data is significantly shortening the timeline for new oncology treatments. For example, AI systems assist in identifying predictive biomarkers and selecting the most effective treatments. These capabilities are crucial for pharmaceutical companies aiming to streamline traditional screening studies and accelerate the bench-to-bedside journey of new cancer therapies.
For instance, scientists at the Institute of Cancer Research, in collaboration with the Spanish biomedical research center Bellvitge Biomedical Research Institute (IDIBELL) and Vivan Therapeutics, are using AI to craft novel treatments aimed at overcoming drug resistance. This joint effort is focused on KRAS gene mutations, which are associated with around 30% of cancers and are especially common in lung and colon cancers. With these cancers, drugs are targeted to inhibit the KRAS mutations, but drug resistance quickly occurs.
Enhancing Cancer Diagnosis
AI tools are now commonly used in healthcare to significantly improve the accuracy of cancer diagnoses. Algorithms are highly effective in analyzing medical images such as computed tomography (CT) scans and mammograms. They can detect tumors and abnormalities with greater accuracy than traditional methods. Moreover, AI helps predict cancer risks based on genetic data and imaging, aiding in early detection and treatment planning.
Innovations like the AI tool developed by researchers at the Massachusetts General Cancer Center and the Massachusetts Institute of Technology demonstrate the power of predictive analytics in oncology. This tool, named Sybil, analyzes low-dose CT scans to predict a patient’s risk of developing lung cancer. The researchers reported that Sybil outperformed other models and achieved 86% to 94% accuracy when predicting a lung cancer diagnosis within the next year. Similarly, the Gemini project at NHS Grampian in Scotland uses an AI program called Mia to enhance mammogram reviews, showing AI’s potential to transform routine diagnostic procedures.
Challenges in Drug Accessibility
Despite these AI-aided advancements in cancer prediction and diagnosis, equal access to new oncology treatments remains a significant challenge around the world. Factors such as geographical location, regulatory hurdles, drug pricing and insurance coverage can restrict access to essential treatments. For example, the costs associated with leading drugs can range from thousands to over one hundred thousand dollars annually, posing an additional barrier to treatment for many patients. Various programs designed to expand access to investigational and approved oncology products can help address these challenges and aim to provide cost-effective options.
Advancing AI Against Cancer
In conclusion, AI is bringing significant advancements in cancer diagnostics and expediting the drug development process. Integrating AI technologies into current practices is expected to further improve accuracy in detecting and diagnosing cancers and may improve personalized treatment strategies. Leveraging AI to refine treatments and expand therapeutic options has the potential to significantly improve patient outcomes. However, despite these technological advances, challenges such as equitable access to these innovative treatments persist, highlighting the need for continued efforts to overcome economic and regulatory barriers. The promise of AI in revolutionizing cancer care is profound, but it necessitates a balanced approach to ensure these lifesaving technologies benefit all individuals, regardless of their socioeconomic or geographical circumstances.
Did you enjoy this blog post? Check out our other blog posts as well as related topics on our Webinar page.
QPS is a GLP- and GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical and clinical drug research development services. Since 1995, it has grown from a tiny bioanalysis shop to a full-service CRO with 1,100+ employees in the U.S., Europe and Asia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine and clinical development. An award-winning leader focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.
